Received Feb 15, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPVHIB | DTAP + IPV + HIB (PENTACEL) | SANOFI PASTEUR | UNK | UK352AA | OT |
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | 1 | — | OT |
mistakenly received pentacel with no AE; patient that received VAXELIS and PENTACEL on the same day, with no reported adverse event; Initial information received on 12-Feb-2026 (follow up received on 12-Feb-2026) regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 2 years old and unknown gender patient who mistakenly received DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(VERO)/HIB(PRP/T) VACCINE [PENTACEL (VERO)] with no ae and patient that received DIPHTHERIA VACCINE TOXOID, HEPATITIS B VACCINE RHBSAG (YEAST), HIB VACCINE CONJ (MENIGOCOCCAL PROTEIN), PERTUSSIS VACCINE ACELLULAR 5-COMPONENT, POLIO VACCINE INACT 3V (VERO), TETANUS VACCINE TOXOID Vaxelis and Pentacel on the same day, with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 03-Feb-2026, the patient mistakenly received a dose 0.5ml (dose 1) of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(VERO)/HIB(PRP/T) VACCINE Suspension for injection, standard strength, lot UK352AA and 28-Feb-2027) and received a dose of VAXELIS not produced by Sanofi Pasteur (expiry date and lot number not reported) via unknown route in unknown administration site for Immunization (wrong product administered) and (extra dose administered) (latency-same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.